Clinical trials: Nash
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease
Optimizing the Beneficial Health Effects of Exercise for Diabetes: Focus on the Liver!
Due to the western lifestyle, correlated with a high calorie intake and low physical activity, obesity is becoming a major health problem. All over the world obesity reaches epidemic proportions.
- Conditions
- Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity
- Trial name
- NCT01317576
- Testing
- Exercise intervention
- Where
- Netherlands
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Bram Brouwers
Non-alcoholic Steatohepatitis (NASH)
FTIH of ECC4703 in Healthy Volunteers
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study of ECC4703 in healthy volunteers and participants with treatment unnecessary LDL-C under 160 mg/dL
- Trial name
- NCT05552274
- Testing
- ECC4703
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Eccogene
MASLD, HIV (Human Immunodeficiency Virus)
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV
Metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease, is increasingly prevalent worldwide.
- Trial name
- MASLD (NCT07640880)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yinzhong Shen
Non-alcoholic Fatty Liver Disease, Fatty Liver
Study of Fish Oil to Reduce ALT Levels in Adolescents
This trial will provide preliminary data to test the hypothesis that a six-month treatment period with fish oil for overweight adolescent with mild to moderate persistent elevation of ALT levels and presence of hepatic steatosis…
- Trial name
- NCT00694746
- Testing
- Omega-3-acid ethyl esters
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Boston University
Nonalcoholic Fatty Liver Disease
Role of Exenatide in NASH-a Pilot Study
We hypothesize that exenatide (Byetta), a GLP-1 agonist administered subcutaneously for 24-28 weeks improves liver histology in diabetic patients with biopsy-proven NASH.
- Trial name
- NAFLD (NCT00650546)
- Testing
- Exenatide
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
This is a Phase 2 multi-center, randomized, single-blind, placebo-controlled study to evaluate the safety and efficacy of TVB-2640 in subjects with non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
- Trial name
- NCT03938246
- Testing
- TVB-2640 25 mg (US), TVB-2640 50 mg (US), TVB-2640 50 mg (China)
- Where
- 23 sites in United States, China
- Volunteers
- 142 people
- Sponsor
- Sagimet Biosciences Inc.
NAFLD, Obesity, Adolescent
Impact of Weight Loss Surgery in Adolescents With NAFLD
This study will assess the impact of weight loss surgery (WLS) on non-alcoholic fatty liver disease (NAFLD) in adolescents as well as the interaction between NAFLD and cardiometabolic risk.
- Trial name
- AWLS (NCT02952170)
- Testing
- MRI
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus
Metabolic Phenotyping and Follow-Up of Patients With and Without Diabetes After New Onset of STEMI
The aim of the prospective observational DISTEMI-Study in people with and without Diabetes mellitus (DI) after new onset of ST-Segment Elevation Myocardial Infarction (STEMI) aged 18-80 years at inclusion into the study is to…
- Conditions
- ST-segment Elevation Myocardial Infarction (STEMI), Diabetes Mellitus, Insulin Resistance, Non-Alcoholic Fatty Liver Disease
- Trial name
- DISTEMI (NCT05046483)
- Where
- Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- German Diabetes Center
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
NAFLD, NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
To the moment, only limited data are present on the efficacy of changes in diet composition of patients with non-alcoholic fatty liver disease (NAFLD).
- Trial name
- 052920190055 (NCT04308980)
- Testing
- Specialized product for medical nutrition (SPP-1), individualized diet
- Where
- Russia
- Volunteers
- 45 people
- Sponsor
- Russian Academy of Medical Sciences
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)
Background: Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disorders characterized by lipid accumulation in hepatocytes. Evidence shows that thyroid hormone might be beneficial for this condition.
- Trial name
- NCT03281083
- Testing
- Levothyroxine Sodium
- Volunteers
- 29 people
- Sponsor
- Duke-NUS Graduate Medical School
Nonalcoholic Steatohepatitis (NASH)
To Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effects of IMM-H014 in Healthy Subjects
This study will evaluate the safety, tolerability and pharmacokinetics (PK) of escalating single- and multiple-oral doses of IMM-H014 on fasted condition, and characterize PK of IMM-H014 on an empty stomach (fasted condition) and…
- Trial name
- NCT06216041
- Testing
- IMM-H014, IMM-H014 ( FE)
- Where
- China
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Changchun Intellicrown Pharmaceutical Co. LTD
Fasting, Intermittent, Diet
Intermittent Fasting Versus Diet to Stop Hypertension on Metabolic Risk Profile in Nonalcoholic Fatty Liver Patients
This study was conducted to compare between the effect of intermittent fasting and diatery approach to stop hypertension on metabolic risk profile in nonalcoholic fatty liver patients.
- Conditions
- Fasting, Intermittent, Diet, Hypertension, Metabolic Syndrome
- Trial name
- NCT06666894
- Testing
- Intermittent fasting, Dietary approach to stop hypertension (DASH)
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Cairo University
Nonalcoholic Fatty Liver Disease
Effect of Treatment With Insulin Sensitizer on Arterial Properties, Metabolic Parameters and Liver Function in Patients With Nonalcoholic Fatty Liver Disease
Abstract Background: Insulin resistance has an important role in the development of nonalcoholic fatty liver disease (NAFLD) and is involved in both pathological processes: hepatic steatosis and atherosclerosis.
- Trial name
- NCT01084486
- Testing
- Metformin
- Where
- Israel
- Sponsor
- Wolfson Medical Center
Non-Alcoholic Steatohepatitis(NASH), Hepatitis C
Blood Collection Biorepository for Liver Disease Research
The purpose of establishing a biorepository is to provide high quality specimens (serum, plasma, buffy coat and liver tissue) for future researchers who are studying the effects that fatty liver and viral diseases have on the…
- Conditions
- Non-Alcoholic Steatohepatitis(NASH), Hepatitis C, Hepatitis B, Fibrosis
- Trial name
- NCT03025074
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
Non Alcoholic Fatty Liver Disease
Safety And Efficacy Study Of Orally Administered Epeleuton In Patients With NAFLD
The purpose of this randomised, double-blind, placebo-controlled, parallel group study is to assess the safety and efficacy of orally administered Epeleuton capsules versus placebo in the treatment of adult patients with Non…
- Trial name
- NCT02941549
- Testing
- Epeleuton
- Where
- 16 sites in Georgia, Ukraine and 1 more
- Volunteers
- 96 people
- Sponsor
- Afimmune
Non-alcoholic Steatohepatitis, Fatty Liver
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
To evaluate the safety and tolerability of Nitazoxanide (NTZ) 500mg Twice Daily (BID) after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis
- Conditions
- Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
- Trial name
- NCT03656068
- Testing
- Nitazoxanide 500mg BID
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Pinnacle Clinical Research, PLLC
NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
- Trial name
- P-CORIGA (NCT07146815)
- Testing
- FibroScan, MRI PDFF
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Ziekenhuis Oost-Limburg
Fatty Liver, Diabetes Mellitus, Type 2
Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
The investigators want to evaluate the effects and safety of ginger in treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- GinLivDM (NCT02289235)
- Testing
- Ginger
- Where
- Iran
- Volunteers
- 76 people
- Sponsor
- Shiraz University of Medical Sciences
Non-Alcoholic Fatty Liver Disease
Multi-Parametric MRI Assessment of the Liver in the Dallas-FortWorth Metroplex Population
To build a Registry of volunteers by inviting them to get a LiverMultiScan(LMS)and collecting their contact information to seek interest in participating in future studies.
- Trial name
- DFWRegistry (NCT04336618)
- Testing
- Liver MultiScan
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Perspectum
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.